John Stagg

2004–2025 年に発表

74
論文数
18,082
被引用数
54
h 指数
71
i10 指数

被引用数

John Stagg の年別被引用数1992 年: 被引用 1 件1996 年: 被引用 1 件1999 年: 被引用 1 件2005 年: 被引用 4 件2006 年: 被引用 14 件2007 年: 被引用 36 件2008 年: 被引用 54 件2009 年: 被引用 59 件2010 年: 被引用 44 件2011 年: 被引用 76 件2012 年: 被引用 90 件2013 年: 被引用 141 件2014 年: 被引用 153 件2015 年: 被引用 204 件2016 年: 被引用 257 件2017 年: 被引用 374 件2018 年: 被引用 343 件2019 年: 被引用 905 件2020 年: 被引用 1,167 件2021 年: 被引用 1,304 件2022 年: 被引用 1,169 件2023 年: 被引用 937 件2024 年: 被引用 1,150 件2025 年: 被引用 639 件2026 年: 被引用 17 件1993〜1995 年は被引用が無いため表示していません1997〜1998 年は被引用が無いため表示していません2000〜2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,009 件、この内訳の 20.6%中国: 引用元論文 1,946 件、この内訳の 20%イタリア: 引用元論文 501 件、この内訳の 5.1%ドイツ: 引用元論文 439 件、この内訳の 4.5%フランス: 引用元論文 400 件、この内訳の 4.1%イギリス: 引用元論文 387 件、この内訳の 4%カナダ: 引用元論文 374 件、この内訳の 3.8%オーストラリア: 引用元論文 282 件、この内訳の 2.9%ベルギー: 引用元論文 225 件、この内訳の 2.3%スペイン: 引用元論文 215 件、この内訳の 2.2%日本: 引用元論文 201 件、この内訳の 2.1%韓国: 引用元論文 180 件、この内訳の 1.9%
0%20.6%その他 26.5%

分野

  • Medicine43%
  • Biochemistry, Genetics and Molecular Biology35.7%
  • Immunology and Microbiology15.3%
  • Engineering3.1%
  • Neuroscience0.8%
  • Materials Science0.6%
  • その他1.5%

トピック

  • Cancer Immunotherapy and Biomarkers10.5%
  • Immunotherapy and Immune Responses5.9%
  • Immune Cell Function and Interaction5.5%
  • Adenosine and Purinergic Signaling4.7%
  • Immune cells in cancer4.1%
  • CAR-T cell therapy research3.9%
  • その他65.4%

共著者

全論文

検索で開く
  1. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

    著者: , , , , , , , , , , , , - Science 2020 被引用: 1,387

  2. Immune evasion in cancer: Mechanistic basis and therapeutic strategies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Beom K. Choi, Byoung S. Kwon - Seminars in Cancer Biology 2015 被引用: 1,653

  3. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sherene Loi, Michael T. Lotze, Gwenola Manic, Taha Merghoub, Alan Melcher, Karen Mossman, Felipe Prósper, Øystein Rekdal, María Rescigno, Chiara Riganti, Antonella Sistigu, Mark J. Smyth, Radek Špíšek, John Stagg, Bryan E. Strauss, Daolin Tang, Kazuki Tatsuno, Stefaan Van Gool, Peter Vandenabeele, Takahiro Yamazaki, Dmitriy Zamarin, Laurence Zitvogel, Alessandra Cesano, Francesco M. Marincola - Journal for ImmunoTherapy of Cancer 2020 被引用: 1,061

  4. The adenosine pathway in immuno-oncology

    著者: , , , - Nature Reviews Clinical Oncology 2020 被引用: 565

  5. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

    著者: , , , - Immunological Reviews 2017 被引用: 895

  6. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 被引用: 427

  7. Consensus guidelines for the detection of immunogenic cell death

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zong Sheng Guo, Akseli Hemminki, Martin Herrmann, James W. Hodge, Stefan Holdenrieder, Jamie Honeychurch, Hong‐Ming Hu, Xing Huang, Tim Illidge, Koji Kono, Mladen Korbelik, Dmitri V. Krysko, Sherene Loi, Pedro R. Löwenstein, Enrico Lugli, Yuting Ma, Frank Madeo, Angelo A. Manfredi, Isabelle Martins, Domenico Mavilio, Laurie Menger, Nicolò Merendino, Michael Michaud, Grégoire Mignot, Karen Mossman, Gabriele Multhoff, Rudolf Oehler, Fabio Palombo, Theocharis Panaretakis, Jonathan Pol, Enrico Proietti, Jean‐Ehrland Ricci, Chiara Riganti, Patrizia Rovere–Querini, Anna Rubartelli, Antonella Sistigu, Mark J. Smyth, Juergen Sonnemann, Radek Špíšek, John Stagg, Abdul Qader Sukkurwala, Éric Tartour, Andrew Thorburn, Stephen H. Thorne, Peter Vandenabeele, Francesca Velotti, Samuel T. Workenhe, Haining Yang, Wei‐Xing Zong, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi - OncoImmunology 2014 被引用: 824

  8. Spatially mapping the immune landscape of melanoma using imaging mass cytometry

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Keith Richardson, Francine Tremblay, Béatrice Wang, May Chergui, Marie‐Christine Guiot, Kevin Watters, John Stagg, Daniela F. Quail, Catalin Mihalcioiu, Sarkis Meterissian, Ian R. Watson - Science Immunology 2022 被引用: 131

  9. Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Angelo A. Manfredi, Stephen R. Mattarollo, Christian Maueröder, Nicolò Merendino, Gabriele Multhoff, Thomas Pabst, Jean‐Ehrland Ricci, Chiara Riganti, Erminia Romano, Nicole Rufo, Mark J. Smyth, Jürgen Sonnemann, Radek Špíšek, John Stagg, Erika Vacchelli, Peter Vandenabeele, Lien Vandenberk, Benoı̂t J. Van den Eynde, Stefaan Van Gool, Francesca Velotti, Laurence Zitvogel, Patrizia Agostinis - Frontiers in Immunology 2015 被引用: 396

  10. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach

    著者: , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2019 被引用: 204

  11. Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

    著者: , , , - Clinical Cancer Research 2013 被引用: 451

  12. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

    著者: , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2017 被引用: 321

  13. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

    著者: , , , , , , , , - Cancer Immunology Research 2015 被引用: 329

  14. Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

    著者: , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2011 被引用: 487

  15. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer

    著者: , , , , , , , , , , , , , , , , - OncoImmunology 2016 被引用: 236

  16. Leveraging big data of immune checkpoint blockade response identifies novel potential targets

    著者: , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 81

  17. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy

    著者: , , , - Science Immunology 2023 被引用: 46

  18. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

    著者: , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 被引用: 490

  19. CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , - Cancer Immunology Research 2022 被引用: 73

  20. CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer

    著者: , , , , , , , , , , , , , , - Cancer Research 2015 被引用: 260

  21. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial

    著者: , , , , , , , , , , , , , , , - Annals of Oncology 2017 被引用: 240

  22. DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Molecular Cell 2021 被引用: 87

  23. Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors

    著者: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 被引用: 343

  24. Immunosuppressive activities of adenosine in cancer

    著者: , , , - Current Opinion in Pharmacology 2016 被引用: 277